Author: admin

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

• DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
• The leading companies working in the Esophageal Squamous Cell Carcinoma Market include BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies in the various stages of development include Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
• December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Tiragolumab and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab, Lenvatinib, Cisplatin, Oxaliplatin, and Levoleucovorin. The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). 

• December 2023: BeiGene announced a study of Phase 2 clinical trials for LBL-007 and Tislelizumab. This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). 

Request a sample and discover the recent advances in Esophageal Squamous Cell Carcinoma Treatment Drugs @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report

In the Esophageal Squamous Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Esophageal Squamous Cell Carcinoma Overview

Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.

Find out more about Esophageal Squamous Cell Carcinoma Therapeutics Assessment @ Esophageal Squamous Cell Carcinoma Preclinical and Discovery Stage Products

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

• Tislelizumab: BeiGene
• Serplulimab: Shanghai Henlius Biotech

Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Esophageal Squamous Cell Carcinoma therapies. The Esophageal Squamous Cell Carcinoma companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Esophageal Squamous Cell Carcinoma Pipeline Therapies @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

• Coverage- Global
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Esophageal Squamous Cell Carcinoma Pipeline Therapies- Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.

Dive deep into rich insights for new drugs for Esophageal Squamous Cell Carcinoma Treatment, Visit @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Esophageal Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tislelizumab: BeiGene
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RAPA-201: Rapa Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SGN-B6A: Seagen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Squamous Cell Carcinoma Key Companies
21. Esophageal Squamous Cell Carcinoma Key Products
22. Esophageal Squamous Cell Carcinoma- Unmet Needs
23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Esophageal Squamous Cell Carcinoma Analyst Views
26. Esophageal Squamous Cell Carcinoma Key Companies
27. Appendix

For further information on the Esophageal Squamous Cell Carcinoma Pipeline therapeutics, reach out to Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Squamous Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

DelveInsight’s, “Advanced Hepatocellular Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape. It covers the Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report

• DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Hepatocellular Carcinoma treatment.
• The leading companies working in the Advanced Hepatocellular Carcinoma market include CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
• Promising Advanced Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include Enzalutamide, ABT-869, Durvalumab, Tremelimumab, Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules, Donafenib Tosilate Tablets, Toripalimab Injection, IBI308 200mg, Lenvatinib, Pembrolizumab, Cabozantinib, AEG35156 antisense IV infusion, Sorafenib, Z-208, Octreotide, and others.
• December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Sorafenib. The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
• December 2023: TaiRx Inc. announced a study of Phase 2 clinical trials for Nivolumab Injection [Opdivo] and CVM-1118. CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.
• On April 2023, Astellas Pharma Inc. announced a study of Phase 2 clinical trials for Enzalutamide. The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS).
• On August 2023, AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab and Tremelimumab. This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
• On August 2023, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. announced a study of Phase 1 Clinical Trials for Penpulimab injection, TQB2618 injection and Anlotinib Hydrochloride Capsules. This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQB2618 injection combined with penpulimab injection and Anlotinib Hydrochloride Capsules in patients with advanced HCC.

Request a sample and discover the recent advances in Advanced Hepatocellular Carcinoma Treatment Drugs @ Advanced Hepatocellular Carcinoma Infection Pipeline Report

The Advanced Hepatocellular Carcinoma  pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Hepatocellular Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Hepatocellular Carcinoma clinical trial landscape.

Advanced Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause of death by cancer each year. Unfortunately, considerable number of patients are diagnosed at advanced stage unsuitable for surgery or local treatment with poor prognosis and a median overall survival (OS) of about 6 months.

Find out more about Advanced Hepatocellular Carcinoma Treatment Landscape @ Drugs for Advanced Hepatocellular Carcinoma Treatment

Advanced Hepatocellular Carcinoma Emerging Drugs Profile

• Tivozanib : AVEO Oncology
• Nofazinlimab: CStone Pharmaceuticals
• ECT 204: Eureka Therapeutics
• Sintilimab: Eli Lilly and Company/Innovent

Advanced Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The Advanced Hepatocellular Carcinoma companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.

DelveInsight’s Advanced Hepatocellular Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Advanced Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Advanced Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Advanced Hepatocellular Carcinoma Pipeline Therapies @ Advanced Hepatocellular Carcinoma Clinical Trials Assessment

Scope of the Advanced Hepatocellular Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co., Geneos Therapeutics, Adaptimmune Therapeutics, and others.
• Advanced Hepatocellular Carcinoma Pipeline Therapies- Enzalutamide, ABT-869, Durvalumab, Tremelimumab, Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules, Donafenib Tosilate Tablets, Toripalimab Injection, IBI308 200mg, Lenvatinib, Pembrolizumab, Cabozantinib, AEG35156 antisense IV infusion, Sorafenib, Z-208, Octreotide, and others.

Dive deep into rich insights for new drugs for Advanced Hepatocellular Carcinoma treatment, Visit @ Advanced Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Nofazinlimab: CStone Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase I/II)
14. Tivozanib : AVEO Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Hepatocellular Carcinoma Key Companies
21. Advanced Hepatocellular Carcinoma Key Products
22. Advanced Hepatocellular Carcinoma – Unmet Needs
23. Advanced Hepatocellular Carcinoma – Market Drivers and Barriers
24. Advanced Hepatocellular Carcinoma – Future Perspectives and Conclusion
25. Advanced Hepatocellular Carcinoma Analyst Views
26. Advanced Hepatocellular Carcinoma Key Companies
27. Appendix

For further information on the Advanced Hepatocellular Carcinoma Pipeline Therapeutics, reach out to Advanced Hepatocellular Carcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Hepatocellular Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

DelveInsight’s, “Brain Metastases Pipeline Insight 2023” report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Brain Metastases Pipeline Report

• DelveInsight’s Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
• The leading companies working in the Brain Metastases Market include HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Promising Brain Metastases Pipeline Therapies in the various stages of development include 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.
• December 2023: GT Medical Technologies Inc. announced a study of Phase 3 clinical trials for Gamma Tile-Surgically Targeted Radiation Therapy (STaRT). This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRS 3-4 weeks following metastatic tumor resection which is the current standard of care.
• December 2023: H. Lee Moffitt Cancer Center and Research Institute announced a study of early Phase 1 clinical trials for Nivolumab and Ipilimumab. The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.

Request a sample and discover the recent advances in Brain Metastases Treatment Drugs @ Brain Metastases Pipeline Outlook Report

In the Brain Metastases pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Brain Metastases Overview

Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

Find out more about Brain Metastases Therapeutics Assessment @ Brain Metastases Preclinical and Discovery Stage Products

Brain Metastases Emerging Drugs Profile

• ANG1005: Angiochem
• Azeliragon: Cantex Pharmaceuticals, Inc.
• AZD3759: Alpha Biopharma Ltd.

Brain Metastases Pipeline Therapeutics Assessment

There are approx. 45+ key companies which are developing the therapies for Brain metastases. The Brain Metastases companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III.

DelveInsight’s Brain Metastases Pipeline Report covers around 45+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Brain Metastases Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Brain Metastases Pipeline Therapies @ Brain Metastases Clinical Trials Assessment

Scope of the Brain Metastases Pipeline Report

• Coverage- Global
• Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Brain Metastases Companies- HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Brain Metastases Pipeline Therapies- 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.

Dive deep into rich insights for new drugs for Brain Metastases Treatment, Visit @ Brain Metastases Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Brain metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Brain metastases– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ANG1005: Angiochem
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Paxalisib: Kazia Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MW151: ImmunoChem Therapeutics, LLC
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. JBI-2174: Jubilant Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Brain metastases Key Companies
21. Brain metastases Key Products
22. Brain metastases- Unmet Needs
23. Brain metastases- Market Drivers and Barriers
24. Brain metastases- Future Perspectives and Conclusion
25. Brain metastases Analyst Views
26. Brain metastases Key Companies
27. Appendix

For further information on the Brain Metastases Pipeline therapeutics, reach out to Brain Metastases Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Brain Metastases Pipeline, FDA Approvals, Clinical Trial Development and Companies 2023

The Advanced Renal Cell Carcinoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Advanced Renal Cell Carcinoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Advanced Renal Cell Carcinoma pipeline landscape and fostering the potential growth of Advanced Renal Cell Carcinoma therapeutic advancements.

Key Takeaways from the Advanced Renal Cell Carcinoma Pipeline Report

• DelveInsight’s Advanced Renal Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Advanced Renal Cell Carcinoma treatment.
• The leading companies working in the Advanced Renal Cell Carcinoma market include Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
• Promising Advanced Renal Cell Carcinoma Pipeline Therapies in the various stages of development include ABT-869, MEDI5752, Axitinib, Lenvatinib, CMN-001, Cabozantinib, Sorafenib, Tivozanib (AV-951), and others.
• December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
• July 2023: Hutchmed Medipharma Limited announced a study of Phase 2 & 3 Clinical Trials for fruquintinib+sintilimab, axitinib / everolimus, and fruquintinib. The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus montherapy as second-line treatment for locally advanced or metastatic renal cell carcinoma.
• August 2023: MedImmune LLC announced a study of Phase 1 Clinical Trials for MEDI5752, Axitinib, and Lenvatinib. The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.
• August 2023: Bristol-Myers Squibb announced a study of Phase 3 Clinical Trials for Nivolumab, Ipilimumab, and Sunitinib. The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Request a sample and discover the recent advances in Advanced Renal Cell Carcinoma Treatment Drugs @ Advanced Renal Cell Carcinoma Pipeline Report

The Advanced Renal Cell Carcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Advanced Renal Cell Carcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Advanced Renal Cell Carcinoma clinical trial landscape.

Advanced Renal Cell Carcinoma Overview

According to the Centers for Disease Control and Prevention (CDC) Trusted Source, Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. This type of cancer develops in the lining of very small tubes, or tubules, inside the kidney. These tubules help to remove waste products from the blood.

Find out more about Advanced Renal Cell Carcinoma Treatment Landscape @ Drugs for Advanced Renal Cell Carcinoma Treatment

Advanced Renal Cell Carcinoma Emerging Drugs Profile

• Belzutifan: Merck Sharp & Dohme
• IPI-549: Infinity Pharmaceuticals
• JANX008: Janux Therapeutics

Advanced Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Advanced Renal Cell Carcinoma. The Advanced Renal Cell Carcinoma companies which have their Advanced Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Merck Sharp & Dohme.

DelveInsight’s Advanced Renal Cell Carcinoma pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Advanced Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Advanced Renal Cell Carcinoma Pipeline Therapies @ Advanced Renal Cell Carcinoma Clinical Trials Assessment

Scope of the Advanced Renal Cell Carcinoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Renal Cell Carcinoma Companies– Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, Infinity Pharmaceuticals, NiKang Therapeutics, Molecure S.A., Daiichi Sankyo, Janux Therapeutics, MedImmune, Eli Lilly and Company, Jiangsu HengRui Medicine Co., Ltd., Allogene Therapeutics, Chongqing Precision Biotech Co., Ltd, Pfizer, Exelixis, BeiGene, Xencor, and others.
• Advanced Renal Cell Carcinoma Pipeline Therapies– ABT-869, MEDI5752, Axitinib, Lenvatinib, CMN-001, Cabozantinib, Sorafenib, Tivozanib (AV-951), and others

Dive deep into rich insights for new drugs for Advanced Renal Cell Carcinoma Treatment, Visit @ Advanced Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Renal Cell Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Belzutifan: Merck Sharp & Dohme
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. IPI-549: Infinity Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. JANX008: Janux Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Renal Cell Carcinoma Key Companies
21. Advanced Renal Cell Carcinoma Key Products
22. Advanced Renal Cell Carcinoma- Unmet Needs
23. Advanced Renal Cell Carcinoma- Market Drivers and Barriers
24. Advanced Renal Cell Carcinoma- Future Perspectives and Conclusion
25. Advanced Renal Cell Carcinoma Analyst Views
26. Advanced Renal Cell Carcinoma Key Companies
27. Appendix

For further information on the Advanced Renal Cell Carcinoma Pipeline therapeutics, reach out to Advanced Renal Cell Carcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Renal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Merck Sharp & Dohme, Chia Tai Tianqing Pharmaceutical, Hoffmann-La Roche, CoImmune, and others.

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2-Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Positive Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HER2-Positive Breast Cancer Pipeline Report

• DelveInsight’s HER2-Positive Breast Cancer pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for HER2-Positive Breast Cancer treatment.
• The leading companies working in the HER2-Positive Breast Cancer Market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
• Promising HER2-Positive Breast Cancer Pipeline Therapies in the various stages of development include TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.
• December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib and Trastuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
• November 2023: University of California, San Francisco announced a study of Phase 2 clinical trials for Neratinib and Loperamide. This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body’s immune system.

Request a sample and discover the recent advances in HER2-Positive Breast Cancer Treatment Drugs @ HER2-Positive Breast Cancer Pipeline Outlook Report

In the HER2-Positive Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2 Positive Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

HER2-Positive Breast Cancer Overview

Breast cancer is not a single disease but a group of diseases. Scientists discovered human epidermal growth factor receptor 2 (HER2)-positive breast cancer when searching for genes that cause cancer. On the most basic level, cancer is the result of normal cells growing unchecked, an observation that led researchers to speculate that specific genes or gene mutations enable this to occur.

Find out more about HER2-Positive Breast Cancer Therapeutics Assessment @ HER2-Positive Breast Cancer Preclinical and Discovery Stage Products

HER2-Positive Breast Cancer Emerging Drugs Profile

• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• HLX11: Shanghai Henlius Biotech
• MCLA-128: Merus N.V.
• DX126 262: Hangzhou DAC Biotech

HER2-Positive Breast Cancer Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for HER2 Positive Breast Cancer. The HER2-Positive Breast Cancer companies which have their HER2 Positive Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.

DelveInsight’s HER2-Positive Breast Cancer pipeline report covers around 65+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

HER2 Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

HER2-Positive Breast Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging HER2-Positive Breast Cancer Pipeline Therapies @ HER2-Positive Breast Cancer Clinical Trials Assessment

Scope of the HER2-Positive Breast Cancer Pipeline Report

• Coverage- Global
• HER2-Positive Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HER2-Positive Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• HER2-Positive Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co. Ltd., Roche, Jiangsu Alphamab Oncology Co. Ltd, Jiangsu HengRui Medicine Co. Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics Inc., Horizon Therapeutics, and others.
• HER2-Positive Breast Cancer Pipeline Therapies- TUKYSA®, Trastuzumab deruxtecan, Tucatinib, Trastuzumab, Pertuzumab, SYSA1901, Docetaxel, and others.

Dive deep into rich insights for new drugs for HER2-Positive Breast Cancer Treatment, Visit @ HER2-Positive Breast Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. HER2 Positive Breast Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Positive Breast Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. MCLA-128: Merus N.V.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. DX126 262: Hangzhou DAC Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. ES2B C001: ExpreS2ion Biotechnologies
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Positive Breast Cancer Key Companies
21. HER2 Positive Breast Cancer Key Products
22. HER2 Positive Breast Cancer- Unmet Needs
23. HER2 Positive Breast Cancer- Market Drivers and Barriers
24. HER2 Positive Breast Cancer- Future Perspectives and Conclusion
25. HER2 Positive Breast Cancer Analyst Views
26. HER2 Positive Breast Cancer Key Companies
27. Appendix

For further information on the HER2-Positive Breast Cancer Pipeline therapeutics, reach out to HER2-Positive Breast Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2-Positive Breast Cancer Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2023,” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Lymphocytic Leukemia Pipeline Report

• DelveInsight’s Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment.
• The leading companies working in the Chronic Lymphocytic Leukemia Market include Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
• Promising Chronic Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Acalabrutinib, ABT-263, Bendamustine, Venetoclax, Rituximab, FCR, and others.
• December 2023: Janssen Research & Development Inc. announced a study of Phase 3 clinical trials for Ibrutinib and Venetoclax. The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
• December 2023: Acerta Pharma BV announced a study of Phase 3 clinical trials for Acalabrutinib and Ibrutinib. This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.
• June 2023: AbbVie announced a study of Phase 1 & 2 Clinical Trials for ABT-263. The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
• July 2023: AstraZeneca announced a study of Phase 3 Clinical Trials for Acalabrutinib. This is a global, Phase 3b, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL).

Request a sample and discover the recent advances in Chronic Lymphocytic Leukemia Treatment Drugs @ Chronic Lymphocytic Leukemia Infection Pipeline Report

The Chronic Lymphocytic Leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Chronic Lymphocytic Leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Chronic Lymphocytic Leukemia clinical trial landscape.

Chronic Lymphocytic Leukemia Overview

Chronic lymphocytic leukemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues, resulting in lymphocytosis, leukemia cell infiltration of the bone marrow, lymphadenopathy, and splenomegaly. The exact etiology of CLL is unknown.

Find out more about Chronic Lymphocytic Leukemia Treatment Landscape @ Drugs for Chronic Lymphocytic Leukemia Treatment

Chronic Lymphocytic Leukemia Emerging Drugs Profile

• Pirtobrutinib: Loxo Oncology
• Cirmtuzumab: Oncternal Therapeutics
• MS-553: MingSight Pharmaceuticals
• NX-2127: Nurix Therapeutics
• NX-5948: Nurix Therapeutics

Chronic Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the therapies for chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia companies which have their chronic lymphocytic leukemia drug candidates in the most advanced stage, i.e. phase III include, Loxo Oncology.

 DelveInsight’s Chronic Lymphocytic Leukemia pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Learn more about the emerging Chronic Lymphocytic Leukemia Pipeline Therapies @ Chronic Lymphocytic Leukemia Clinical Trials Assessment

Scope of the Chronic Lymphocytic Leukemia Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Chronic Lymphocytic Leukemia Companies– Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
• Chronic Lymphocytic Leukemia Pipeline Therapies– Acalabrutinib, ABT-263, Bendamustine, Venetoclax, Rituximab, FCR, and others.

Dive deep into rich insights for new drugs for Chronic Lymphocytic Leukemia treatment, Visit @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Chronic lymphocytic leukemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic lymphocytic leukemia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pirtobrutinib: Loxo Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cirmtuzumab: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NX-2127: Nurix Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic lymphocytic leukemia Key Companies
21. Chronic lymphocytic leukemia Key Products
22. Chronic lymphocytic leukemia- Unmet Needs
23. Chronic lymphocytic leukemia- Market Drivers and Barriers
24. Chronic lymphocytic leukemia- Future Perspectives and Conclusion
25. Chronic lymphocytic leukemia Analyst Views
26. Chronic lymphocytic leukemia Key Companies
27. Appendix

For further information on the Chronic Lymphocytic Leukemia pipeline therapeutics, reach out to Chronic Lymphocytic Leukemia Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Lymphocytic Leukemia Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 | Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics and Others

DelveInsight’s, “Cholangiocarcinoma Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cholangiocarcinoma Pipeline Report

• DelveInsight’s Cholangiocarcinoma pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma treatment.
• The leading companies working in the Cholangiocarcinoma Market include Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Promising Cholangiocarcinoma Pipeline Therapies in the various stages of development include Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.
• December 2023: TransThera Sciences (Nanjing) Inc., announced a study of Phase 3 clinical trials for Tinengotinib 8 mg. This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma.
• December 2023: Tyra Biosciences Inc. announced a study of Phase 1 clinical trials for Phase 1 Part A – dose escalation TYRA-200 taken once daily by mouth in 28-day cycles. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.
• December 2023: Incyte Corporation announced a study of Phase 3 clinical trials for Pemigatinib, Gemicitabine, and Cisplatin. The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.
• December 2023: Servier announced a study of Phase 2 clinical trials for Ivosidenib. This study will enroll participants with nonresectable or metastatic cholangiocarcinoma with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have previously received at least 1, but no more than 2, prior regimens for advanced disease. All participants will receive ivosidenib daily throughout multiple 28 day cycles.

Request a sample and discover the recent advances in Cholangiocarcinoma Treatment Drugs @ Cholangiocarcinoma Pipeline Outlook Report

In the Cholangiocarcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Cholangiocarcinoma Overview

Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree and showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma. Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections.

Find out more about Cholangiocarcinoma Therapeutics Assessment @ Cholangiocarcinoma Preclinical and Discovery Stage Products

Cholangiocarcinoma Emerging Drugs Profile

• Pembrolizumab: Merck Sharp & dohme
• E7090: Eisai
• ABC294640: RedHill Biopharma Limited
• TT-00420: TransThera Science
• KIN-3248: Kinnate Biopharma

Cholangiocarcinoma Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Cholangiocarcinoma therapies. The Cholangiocarcinoma companies which have their Cholangiocarcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck Sharp & dohme.

DelveInsight’s Cholangiocarcinoma pipeline report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Cholangiocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Cholangiocarcinoma Pipeline Therapies @ Cholangiocarcinoma Clinical Trials Assessment

Scope of the Cholangiocarcinoma Pipeline Report

• Coverage- Global
• Cholangiocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cholangiocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cholangiocarcinoma Companies- Merck Sharp & dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, Taiho Oncology, Bristol-Myers Squibb, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., GlaxoSmithKline, Beijing InnoCare Pharma, Genoscience, 3D Medicines, Innovent Biologics (Suzhou) Co. Ltd., QED Therapeutics, Hutchison MediPharma, TriSalus Life Sciences, Relay Therapeutics, Eli Lilly and Company, Medivir, Boehringer Ingelheim, Compass Therapeutics, Intensity Therapeutics, Sirnaomics, Wellmarker Bio, and others.
• Cholangiocarcinoma Pipeline Therapies- Tinengotinib 8 mg, Ivosidenib, CX-4945, Cisplatin, Gemcitabine, E7090, Pemigatinib, and others.

Dive deep into rich insights for new drugs for Cholangiocarcinoma Treatment, Visit @ Cholangiocarcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Cholangiocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cholangiocarcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pembrolizumab: Merck Sharp & dohme
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. E7090: Eisai
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. KIN-3248: Kinnate Biopharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cholangiocarcinoma Key Companies
21. Cholangiocarcinoma Key Products
22. Cholangiocarcinoma- Unmet Needs
23. Cholangiocarcinoma- Market Drivers and Barriers
24. Cholangiocarcinoma- Future Perspectives and Conclusion
25. Cholangiocarcinoma Analyst Views
26. Cholangiocarcinoma Key Companies
27. Appendix

For further information on the Cholangiocarcinoma Pipeline therapeutics, reach out to Cholangiocarcinoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cholangiocarcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Merck Sharp & Dohme, Eisai, RedHill Biopharma Limited, TransThera Science, Kinnate Biopharma, and others.